Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06655246

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Led by Kura Oncology, Inc. · Updated on 2026-02-05

157

Participants Needed

32

Research Sites

192 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.

CONDITIONS

Official Title

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Documented diagnosis of advanced or metastatic KIT-mutant gastrointestinal stromal tumor (GIST)
  • Documented disease progression on imatinib as current or prior therapy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less at screening
  • At least 1 measurable lesion according to RECIST v1.1 modified for GIST
  • Negative pregnancy test for participants who can become pregnant
  • Adequate organ function as defined by the study protocol
  • All significant toxicities from prior therapy resolved to less than Grade 1 or baseline within 1 week before first dose
  • Ability to understand and sign written informed consent before screening
Not Eligible

You will not qualify if you...

  • GIST diagnosis without a KIT mutation or with a T670X KIT mutation
  • History of other cancers that could interfere with study results
  • Use of prohibited medications or investigational therapy within 14 days or 5 half-lives before first dose
  • Active metastases in the central nervous system
  • Uncontrolled illnesses including cardiac disease defined by the protocol
  • Mean corrected QT interval (QTcF) over 470ms
  • Left ventricular ejection fraction (LVEF) below 50%
  • Major surgery within 2 weeks before first dose
  • Pregnancy or breastfeeding
  • Gastrointestinal problems affecting oral medication intake
  • Active bleeding except minor bleeding like hemorrhoids or gums

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 32 locations

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

Mayo Clinic Cancer Center

Phoenix, Arizona, United States, 85054

Actively Recruiting

3

University of California, San Diego

La Jolla, California, United States, 92093

Actively Recruiting

4

University of Southern California

Los Angeles, California, United States, 90033

Actively Recruiting

5

University Of California, Irvine

Orange, California, United States, 92868

Actively Recruiting

6

Stanford Cancer Institute

Palo Alto, California, United States, 94304

Actively Recruiting

7

UCLA Santa Monica Medical Center

Santa Monica, California, United States, 90404

Actively Recruiting

8

University of Colorado Cancer Center

Aurora, Colorado, United States, 80045

Actively Recruiting

9

Sarah Cannon Research Institute

Denver, Colorado, United States, 80220

Actively Recruiting

10

Yale University School of Medicine

New Haven, Connecticut, United States, 06511

Actively Recruiting

11

Mayo Clinic Cancer Center

Jacksonville, Florida, United States, 32224

Actively Recruiting

12

University of Miami

Miami, Florida, United States, 33136

Actively Recruiting

13

Northwestern University

Chicago, Illinois, United States, 60611

Actively Recruiting

14

University of Iowa

Iowa City, Iowa, United States, 52242

Actively Recruiting

15

Johns Hopkins University

Baltimore, Maryland, United States, 21287

Actively Recruiting

16

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

17

Harvard University

Boston, Massachusetts, United States, 02215

Actively Recruiting

18

University of Michigan

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

19

Mayo Clinic Cancer Center

Rochester, Minnesota, United States, 55905

Actively Recruiting

20

Memorial Sloan-Kettering Cancer Center

New York, New York, United States, 10065

Actively Recruiting

21

Duke University Medical Center

Durham, North Carolina, United States, 27710

Actively Recruiting

22

Ohio State University

Columbus, Ohio, United States, 43210

Actively Recruiting

23

Oregon Health & Science University

Portland, Oregon, United States, 97239

Actively Recruiting

24

Thomas Jefferson University

Philadelphia, Pennsylvania, United States, 19107

Actively Recruiting

25

Temple University Health System

Philadelphia, Pennsylvania, United States, 19111

Actively Recruiting

26

Sarah Cannon Research Institute

Nashville, Tennessee, United States, 37203

Actively Recruiting

27

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

28

Sarah Cannon Research Institute

Dallas, Texas, United States, 75230

Actively Recruiting

29

University of Texas

Houston, Texas, United States, 77030

Actively Recruiting

30

University of Texas Health Science Center

San Antonio, Texas, United States, 78229

Actively Recruiting

31

University of Utah

Salt Lake City, Utah, United States, 84112

Actively Recruiting

32

Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Actively Recruiting

Loading map...

Research Team

K

Kura Medical Information 844-KURAONC

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here